- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02740179
Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
June 2, 2023 updated by: Steven K. Grinspoon, MD, Massachusetts General Hospital
Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study
HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals.
A hormone called aldosterone, which regulates blood pressure and sodium balance, is elevated in the HIV population in association with with increased belly fat and altered glucose metabolism.
Elevations in aldosterone hormone may also be associated with abnormal blood flow, inflammation, and coronary plaque in the heart.
This study is being conducted to evaluate whether therapies to reduce the actions of aldosterone may decrease the burden and progression of heart disease in the HIV population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a 12 month randomized, placebo controlled study enrolling HIV-infected individuals with no known history of cardiovascular disease.
Eplerenone is a mineralocorticoid receptor antagonist, which can block aldosterone activation.
This medication is approved by the FDA for high blood pressure and heart failure.
This study aims to investigate the effect of eplerenone on other measures of cardiovascular disease in HIV.
Using PET, MRI, and CT imaging technology, this study will evaluate whether eplerenone can improve coronary flow reserve and myocardial inflammation/fibrosis, in addition to atherosclerotic plaque build-up among the HIV population.
The study also includes teaching on lifestyle modification to promote a healthy diet and exercise program.There are 3 overnight visits in addition to safety visits.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ages 40-65 years
- Antiretroviral use (ART) >12 months and HIV viral load <100 copies/mL
- VAT> 110cm2
Exclusion Criteria:
- Antihypertensive use including, ACE Inhibitor, ARB, MR blockade, diuretic, potassium (K) supplementation; or BP>140/90 mmHg. Stable use (>3 months) of beta-blockers or calcium channel blockers (CCB) (except verapamil) is allowed.
- Unstable statin use <12 months. Stable use (>12 months) is allowed.
- Use of full dose ritonavir, nelfinavir, clarithromycin, and other strong inhibitors of CYP3A4, as well as CYP3A4 inducers.
- Continuous oral steroid use (equivalent to prednisone > 5 mg daily) within the last 3 months.
- Uncontrolled diabetes requiring insulin and/or HbA1c > 7.5%.
- Creatinine (Cr) > 1.5 mg/dL or estimated GFR<60 mL/min/1.73m2.
- K > 5.5 mEq/L.
- Hemoglobin < 10 g/dL.
- Known liver disease or ALT >3x ULN.
- History of congestive heart failure, stroke, myocardial infarction, or known coronary artery disease.
- Pregnant, actively seeking pregnancy or breastfeeding.
- Estrogen, progestin derivative, or other sex steroid use within last 3 months. Stable physiologic testosterone replacement (> 3 months) is acceptable.
- Current bacterial or other infections.
- Active substance abuse.
- Significant radiation exposure over the course of the year prior to randomization (e.g., radiation therapy, PCI, catheter ablation of arrhythmia) within 12 months of randomization.
- Previous reaction or contraindication to iodine-containing contrast media and gadolinium.
- Coronary artery luminal narrowing >70% on coronary CTA.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eplerenone
Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
|
Eplerenone 50mg by mouth twice daily
Counseling regarding diet and healthy activity
|
Placebo Comparator: Placebo
Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
|
Counseling regarding diet and healthy activity
Placebo by mouth twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Myocardial Perfusion by MRI
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by myocardial blood flow measured via cardiac magnetic resonance imaging
|
12 Months
|
Myocardial Inflammation
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in myocardial inflammation measured by extracellular mass index (a measure of the inflammation within the heart) via cardiac magnetic resonance imaging
|
12 Months
|
Myocardial Perfusion by PET
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by coronary flow reserve measured via cardiac positron emission tomography.
Coronary flow reserve is given by the ratio of blood flow at stress during maximal dilation of the coronary arteries to blood flow at rest.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coronary Plaque
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in coronary plaque measured via coronary computed tomography angiogram assessed by coronary calcium score Scale: minimum 0 to maximum no limit, higher score indicates more plaque
|
12 Months
|
Markers of Vascular Dysfunction
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in serum hs-cTnT
|
12 Months
|
Markers of Systemic Inflammation hsIL-6
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in plasma hsIL-6
|
12 Months
|
Markers of Systemic Inflammation hsCRP
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in plasma hsCRP
|
12 Months
|
Markers of Immune Activation MCP-1
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in plasma MCP-1
|
12 Months
|
Markers of Immune Activation sCD163
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in plasma sCD163
|
12 Months
|
Markers of Subclinical Injury
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in serum NT-proBNP
|
12 Months
|
Markers of Fibrosis
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in myocardial fibrosis measured by T1 (a signal intensity that measures fibrosis) via cardiac magnetic resonance imaging
|
12 Months
|
Arterial Inflammation
Time Frame: 12 Months
|
Percentage change (value at 12 months minus value at baseline) in target to background ratio (a measure of arterial inflammation) of the index vessel measured via positron emission tomography/computed tomography
|
12 Months
|
Markers of Arterial Inflammation
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in plasma LpPLA2
|
12 Months
|
Assessment of Cardiac Structure by Left Ventricular Mass on Cardiac Imaging
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in left ventricular mass on cardiac magnetic resonance imaging
|
12 Months
|
Assessment of Cardiac Systolic Function Via Cardiac Imaging
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in global circumferential strain (GCS) on cardiac magnetic resonance imaging
|
12 Months
|
Assessment of Cardiac Diastolic Function Via Cardiac Imaging
Time Frame: 12 Months
|
Change (value at 12 months minus value at baseline) in left ventricular end diastolic volume on cardiac magnetic resonance imaging
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2017
Primary Completion (Actual)
March 17, 2022
Study Completion (Actual)
March 17, 2022
Study Registration Dates
First Submitted
April 7, 2016
First Submitted That Met QC Criteria
April 13, 2016
First Posted (Estimated)
April 15, 2016
Study Record Updates
Last Update Posted (Actual)
June 6, 2023
Last Update Submitted That Met QC Criteria
June 2, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016P000464
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Eplerenone
-
Tufts Medical CenterCompleted
-
Vanderbilt University Medical CenterNational Center for Research Resources (NCRR)Completed
-
Darnitsa Pharmaceutical CompanyACDIMA BiocenterCompletedHealthy Subjects | BioequivalenceJordan
-
Pr. Nicolas GIRERDRecruitingKidney Transplantation for More Than One Year | Patients With a Kidney Transplantation on CyclosporineFrance
-
University of CincinnatiWithdrawnLow Back Pain | Sciatic Radiculopathy | Degenerative Intervertebral DiscsUnited States
-
Subha RamanBallou SkiesCompletedDuchenne Muscular DystrophyUnited States
-
Semmelweis UniversityCompletedChronic Central Serous ChorioretinopathyHungary
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHealthy VolunteersUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)WithdrawnHypertensionUnited States